Newly diagnosed acute promyelocytic leukemia

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Avvisati, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870371149     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.064     Document Type: Article

References (69)

1. Avvisati G, ten Cate JW, Mandelli F: Acute promyelocytic leukaemia. Br J Haematol 1992; 81: 315-320; http://dx.doi.org/10.1111/j.1365-2141.1992.tb08233.x PMid:1390205
2. Warrell RP, de Thé H, Wang ZY, Degos L: Acute promyelocytic leukemia. N Engl J Med 1993; 329: 177-189; http://dx.doi.org/10.1056/NEJM199307153290307 PMid:8515790
3. Rowley JD, Golomb HM, Dougherty C: 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukemia Lancet 1977; i: 549-550; http://dx.doi.org/10.1016/S0140-673691415-5 PMid:65649
4. Grignani F, Fagioli M, Alcalay M et al: Acute promyelocytic leukemia: from genetic to treatment. Blood 1994; 83: 10-25; PMid:8274729
5. Borrow J, Goddard AD, Sheer D, Solomon E: Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17 Science 1990; 249: 1577-1582; PMid: 2218500
6. Longo L, Pandolfi PP, Biondi A et al: Rearrangements and aberrant expression of the retinoid acid receptor alpha gene in acute promyelocytic leukemia. J Exp Med 1990; 172: 1571-1575; http://dx.doi.org/10.1084/jem.172.6.1571 PMid:2175343
7. Kakizuka A, Miller WH Jr, Umesono K et al: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML Cell 1991; 66: 663-674; http://dx.doi.org/10.1016/0092-8674(91)90112-C PMid:1652368
8. Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.
9. Hillestad LK. Acute promyelocytic leukemia. Acta Med Scand 1957;159:189-194 http://dx.doi.org/10.1111/j.0954-6820.1957.tb00124.x PMid:13508085
10. Bernard J, Mathé G, Boulay J et al: La leucose aiguë à promyélocytes Schweiz Med Wochenschr 1959; 89:604-8; PMid:13799642
11. Bernard J, Boiron M, Lortholary P, Levy JP. The very acute leukemias Cancer Research 1965; 25: 1675-1676; PMid:5217030
12. Tallman MS, Nabhan C, Feusner JH, Rowe JM. Acute promyelocytic leukemia: evolving therapeutic strategies. Blood 2002; 99:759-767 http://dx.doi.org/10.1182/blood. V99.3.759 PMid:11806975
13. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009; 113:1875-1891 http://dx.doi.org/10.1182/blood-2008-04-150250 PMid:18812465
14. Tallman MS, Altman JK. How I treat acute promyelocytic leukemia. Blood 2009; 114: 5126-5135 http://dx.doi.org/10.1182/blood-2009-07-216457 PMid:19797519
15. Huang ME, Ye YC, Chen SR, et al.: Use of all trans-retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72: 567-572 PMid:3165295
16. Fenaux P, Le Deley MC, Castaigne S, et al.: Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993;82:3241-3249; PMid:8241496
17. Tallman MS, Andersen JW, Schiffer CA, et al: All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337:1021-1028 http://dx.doi.org/10.1056/NEJM199710093371501 PMid:9321529
18. Asou N, Adachi K, Tamura J, et al.: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998; 16:78-85; PMid:9440726
19. Sanz MA, Vellenga E, Rayón C, et al.: All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004; 104:3490-3493; http://dx.doi.org/10.1182/blood-2004-04-1642 PMid:15292063
20. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997; 90:1014-1021; PMid:9242531
21. Di Bona E, Avvisati G, Castaman G, et al.: Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000; 108:689-695; http://dx.doi.org/10.1046/j.1365-2141.2000.01936.x PMid:10792270 PMid:10792270
22. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91:3093-3102 PMid:9558362
23. Falanga A, Iacoviello L, Evangelista V, et al. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-transretinoic acid. Blood 1995; 86:1072-1091; PMid:7620161
24. Adès L, Guerci A, Raffoux E, et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood 2010; 115:1690-1696 http://dx.doi.org/10.1182/blood-2009-07-233387 PMid:20018913
25. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF: Acute promyelocytic leukemia: results of treatment by daunorubicin. Blood 1973; 41:489-496. PMid:4510926
26. Marty M, Ganem G, Fischer J, et al: Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin. Nouv Rev Fr Hematol 1984;26:371-378. PMid:6597407
27. Petti MC, Avvisati G, Amadori S, et al: Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients. Haematologica 1987;72:151-155. PMid:3114070
28. Sanz MA, Jarque I, Martin G, et al: Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 1988; 61:7-13. http://dx.doi.org/10.1002/1097-0142(19880101)61:1<7::AIDCNCR2820610103> 3.0.CO;2-6 PMid:3422032
29. Avvisati G, Mandelli F, Petti MC, et al: Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44:257-260. http://dx.doi.org/10.1111/j.1600-0609.1990.tb00389.x PMid:2188854
30. Paietta E, Andersen J, Racevskis J, et al: Significantly lower Pglycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994;8:968-973; PMid:7516029
31. Michieli M, Damiani D, Ermacora A, et al: P-glycoprotein (PGP), lung resistance-related protein (LRP) and multidrug resistanceassociated protein (MRP) expression in acute promyelocytic leukaemia. Br J Haematol 2000;108:703-709. http://dx.doi.org/10.1046/j.1365-2141.2000.01957.x PMid:10792272
32. Takeshita A, Shinjo K, Naito K, et al: Role of P-glycoprotein in all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukaemia cells: analysis of intracellular concentration of ATRA. Br J Haematol 2000; 108:90-92; http://dx.doi.org/10.1046/j.1365-2141.2000.01823.x PMid:10651729
33. Candoni A, Damiani D, Michelutti A, et al. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leucemia. Eur J Haematol 2003;71:1-8; http://dx.doi.org/10.1034/j.1600-0609.2003.00084.x PMid:12801292 PMid:12801292
34. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group: Blood 1999; 94:1192-1200; PMid:10438706
35. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol: Blood 2002;100:4298-4302; http://dx.doi.org/10.1182/blood-2002-02-0632 PMid:12393590
36. Burnett AK, Grimwade D, Solomon E, et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999; 93:4131-4143; PMid:10361110
37. Adès L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24:5703-5710 http://dx.doi.org/10.1200/JCO.2006.08.1596 PMid:17116939
38. Sanz MA, Martín G, Rayón C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalphapositive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94:3015-3021; PMid:10556184
39. Lo-Coco F, Avvisati G, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood 2010; 116:3171-3179; http://dx.doi.org/10.1182/blood-2010-03-276196 PMid:20644121
40. Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011; 117:4716-4725. http://dx.doi.org/10.1182/blood-2010-08-302950 PMid:21385856
41. Adès L, Sanz MA, Chevret S, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008; 111:1078-1084; PMid:17975017
42. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008; 111:3395-3402; http://dx.doi.org/10.1182/blood-2007-07-100669 PMid:18195095
43. Avvisati G, Lo-Coco F, Diverio D, et al.: AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study. Blood 1996; 88:1390-1398; PMid:8695858
44. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22. PMid:10381493
45. Grimwade D, Lo Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-1973; http://dx.doi.org/10.1038/sj.leu.2402721 PMid:12357347
46. Cheson BD, Bennett JM, Kopecky K, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642-4649; http://dx.doi.org/10.1200/JCO.2003.04.036 PMid:14673054
47. Sanz MA, Lo Coco F, Martin G, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leucemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000; 96: 1247-1253; PMid:10942364
48. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137-5146; http://dx.doi.org/10.1182/blood-2010-01-266007 PMid:20393132 PMid:20393132
49. Asou N, Kishimoto Y, Kiyoi H, et al.: A randomized study with or witout intensified maintenance chemotherapy in patients with acute promyelocytic leukemia wo have become negative for PMLRARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL 97 study. Blood 2007;110:59-66 http://dx.doi.org/10.1182/blood-2006-08-043992 PMid:17374742
50. Vahdat L, Maslak P, Miller WH Jr, et al.: Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patientstreated with all-trans retinoic acid. Blood 1994;84:3843-3849; PMid:7949141
51. Montesinos P, Bergua JM, Vellenga E, et al.: Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood 2009; 113:775-783; http://dx.doi.org/10.1182/blood-2008-07-168617 PMid:18945964
52. Kelaidi C, Chevret S, De Botton S, et al.: Improved outcome of acute promyelocytic leucemia with high WBC counts over the last 15 years: the European APL Group experience. J Clin Oncol 2009; 27:2668-2676; http://dx.doi.org/10.1200/JCO.2008.18.4119 PMid:19414681
53. Mahmoud HH, Hurwitz CA, Roberts WM, et al.:Tretinoin toxicity in children with acute promyelocytic leukemia. Lancet 1993;342:1394-1395; http://dx.doi.org/10.1016/0140-6736(93)92755-I PMid: 7901684
54. Cardonick E, Iacobucci A. Use of chemotherapy during human preganancy. Lancet Oncol 2004; 5:283-291; http://dx.doi.org/10.1016/S1470-2045(04)01466-4 PMid:15120665
55. Giagounidis AAN, Beckmann MW, Giagounidis AS, et al. Acute promyelocytic leukemia and pregnancy. Eur J Haematol. 2000;64:267-271; http://dx.doi.org/10.1034/j.1600-0609.2000.9c118.x PMid:10776699
56. Beaumont M, Sanz M, Carli PM, et al. Therapy related acute promyelocytic leukemia. J Clin Oncol 2003;21: 2133-2137; http://dx.doi.org/10.1200/JCO.2003.09.072 PMid:12775738
57. Mandelli F, Latagliata R, Avvisati G, et al. Treatment of elderly patients (> 60 years) with newly diagnosed acute promyelocytic leukaemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 2003; 17:1085-1090; http://dx.doi.org/10.1038/sj.leu.2402932 PMid:12764372
58. Sanz MA, Vellenga E, Rayon C, et al. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood 2004;104:3490-3493; http://dx.doi.org/10.1182/blood-2004-04-1642 PMid:15292063
59. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001;80:417-422; http://dx.doi.org/10.1007/s002770100304 PMid:11529468
60. De Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol 2004;22:1404-1412; http://dx.doi.org/10.1200/JCO.2004.09.008 PMid:150846144
61. Testi AM, Biondi A, Lo Coco F, et al.: GIMEMA AIEOP AIDA protocol for the treatment of newly diagnosed promyelocytic leukemia in children. Blood 2005 Jul 15;106:447-453. PMid: 15677559
62. Specchia G, Lo-Coco F, Vignetti M, et al. Extramedullary involvement at relapse in acute promyelocytic leukemia patients treated or not with ATRA. A report by the GIMEMA Group. J Clin Oncol 2001;19:4023-4028; PMid:11600603
63. Breccia M, Diverio D, Noguera NI, et al.: Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapy. Haematologica 2004;89:29-33; PMid:14754603
64. Niu C, Yan H, Yu T, et al.: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999;94:3315-3324; PMid:10552940
65. Mathews V, George B, Lakshmi KM, et al.: Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627-2632; http://dx.doi.org/10.1182/blood-2005-08-3532 PMid:16352810
66. Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469-3473. http://dx.doi.org/10.1182/blood-2005-10-4006 PMid:16373661
67. Hu J, Liu YF, Wu CF, et al.: Long-term efficacy and safety of alltrans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009;106:3342-3347; http://dx.doi.org/10.1073/pnas.0813280106 PMid:19225113 PMCid:2651325
68. Ravandi F, Estey E, Jones D, et al.: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol. 2009;27:504-510; http://dx.doi.org/10.1200/JCO.2008.18.6130 PMid:19075265
69. Mathews V, George B, Chendamarai E, Lakshmi KM, Desire S, Balasubramanian P, Viswabandya A, Thirugnanam R, Abraham A, Shaji RV, Srivastava A, Chandy M. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol. 2010;28:3866-3871; http://dx.doi.org/10.1200/JCO.2010.28.5031 PMid:20644086